Temple: FDASIA Directs FDA To Learn To Use Existing Authority
CDER’s Robert Temple says FDASIA mostly restates existing FDA authority, but also tells the agency it must better communicate what authority it has and how it will use it.
You may also be interested in...
House opioid package includes ability to deny or withdraw products because of abuse potential, but new Senate package does not, setting up potential conference battle.
A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.
White House sends out short press release as FDA is conducting an unrelated briefing to announce the user fee bill was enacted, surprising stakeholders and generating political questions.